Skip to content
Unknown statusPhase 2

Psilocybin for Treatment of Alcohol Use Disorder: a Feasibility Study

NCT04718792 · Anders Fink-Jensen, MD, DMSci

Closed to entry
Status
Not accepting participants
Phase 2
Phase
10
Target enrolment
1
Study sites
Outside the US

What it is testing

Summary

The purpose of this project is to assess the feasibility and safety of administering a single dose of psilocybin to patients diagnosed with alcohol use disorder (AUD). In addition the investigators will establish the pharmacokinetic properties of the active metabolite psilocin. This is the first step in a research project that has the overall aim to evaluate the efficacy of a single administration of psilocybin as an intervention for treatment of AUD.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • Safety: Adverse events associated with administration of psilocybin in patients diagnosed with alcohol use disorder

    Measured over 12 week after drug administration

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

20 Years to 70 Years
Ages
All
Sex
Not accepted
Healthy volunteers
Inclusion Criteria: 1. Age of 20-70 years (both included). 2. Body weight of 60-95 kg (both included). 3. Diagnosed with AUD according to DSM-5 criteria and alcohol dependence according to ICD-10. 4. Alcohol Use Disorder Identification Test (AUDIT) ≥ 15. 5. ≥ 5 heavy drinking days. Exclusion Criteria: 1. Personal or first-degree relatives with current or previous diagnosis within psychotic spectrum disorders or bipolar disorder. 2. History of delirium tremens or alcohol withdrawal seizures. 3. History of suicide attempt or present suicidal ideation. 4. Withdrawal symptoms at inclusion, defined as a score higher than 9 on the Clinical Institute Withdrawal Assessment of Alcohol Scale, Revised (CIWA-Ar). 5. Present or former severe neurological disease including head trauma with loss of consciousness \> 30 min. 6. Impaired hepatic function (liver transaminases \> 3 times upper normal limit). 7. Cardiac problems defined as decompensated heart failure (NYHA class III or IV), unstable angina pectoris and/or myocardial infarction within the last 12 months. 8. Abnormal electrocardiogram 9. Impaired renal function (eGFR \< 50 ml/min). 10. Uncontrolled hypertension (systolic blood pressure \>165 mmHg, diastolic blood pressure \>95 mmHg). 11. Pharmacotherapy against AUD including disulfiram, naltrexone, acamprosate and nalmefene or treatment with any of these compounds within 28 days prior to inclusion. 12. Treatment with any serotonergic medication or any use of serotonergic psychedelics within 1 month prior to inclusion. 13. Any other active substance use defined as a Drug Use Disorder Identification Test score \> 6/2 (m/w) and substance use disorder based on investigator's clinical evaluation, except for nicotine. 14. Women of childbearing potential who are pregnant, breastfeeding or have intention of becoming pregnant or are not using adequate contraceptive measures considered highly effective61. 15. Hypersensitivity to the active substance or to any of the excipients. 16. Unable to speak and/or understand Danish. 17. Any condition that the investigator feels would interfere with trial participation.

Where

1 study site

FacilityCityRegionCountry
Psychiatric Center CopenhagenCopenhagenFrederiksbergDenmark

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT04718792 on ClinicalTrials.gov →

Last updated in the registry 2024-07-12. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits